234 related articles for article (PubMed ID: 35060807)
21. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
[TBL] [Abstract][Full Text] [Related]
22. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
[TBL] [Abstract][Full Text] [Related]
23. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
[No Abstract] [Full Text] [Related]
25. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
26. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Duvic M; Sloan JM; Spence S; Shemesh S; Brooks CL; Balser J; Bergstein I; Lancet JE; Kantarjian HM; Konopleva M
N Engl J Med; 2019 Apr; 380(17):1628-1637. PubMed ID: 31018069
[TBL] [Abstract][Full Text] [Related]
27. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
28. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
29. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
Beziat G; Ysebaert L
Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
[TBL] [Abstract][Full Text] [Related]
30. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
[No Abstract] [Full Text] [Related]
31. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
32. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
33. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
34. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Hammond D; Pemmaraju N
Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
[TBL] [Abstract][Full Text] [Related]
35. Targeting CD123 in AML.
Lane AA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S67-S68. PubMed ID: 32862874
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
37. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
38. Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Morin A; Kechedjian F; Walton P; Tavakoli A
Clin J Oncol Nurs; 2021 Apr; 25(2):E10-E16. PubMed ID: 33739343
[TBL] [Abstract][Full Text] [Related]
39. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
40. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
Wu SJ; Sadigh S; Lane AA; Pinkus GS
Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
